ArrayPatch
ArrayPatch Ltd is a Cork, Ireland-based biotech developing polymer-free dissolving microneedle therapeutics via its DerMap platform, with lead program ITZ-DerMap for nail fungal infections and a pipeline expanding into dermatology, migraine, and peptide therapy indications.
- Company typePrivate
- Founded2024
- HeadquartersCork, Ireland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What ArrayPatch does
ArrayPatch Ltd is a Cork, Ireland-based, privately held biotech founded in 2024 that develops therapeutics using its proprietary DerMap microneedle patch platform. DerMap is described as a coin-sized, pain-free patch whose microneedles penetrate the outer skin layer and dissolve to release medication; the key technical claim is that each microneedle is fabricated entirely from the active drug substance itself, eliminating the polymers used in older dissolving-microneedle systems and enabling higher drug loading per patch. The company is pursuing the 505(b)(2) regulatory route for its lead program ITZ-DerMap, targeting onychomycosis (nail fungal infection) within an underserved dermatology market, with stated focus on high-risk diabetic patients and a stated first-product approval target of 3-4 years. The platform is positioned as broadly applicable, with the company publicly listing expansion plans into skin cancer, skin ageing, migraines, and peptide therapies.
The pipeline was extended in April 2026 through the acquisition of peptide delivery technology from Vitropep, broadening the platform into peptide therapeutics for diabetes and cardiovascular disease. ArrayPatch is pre-commercial with no disclosed revenue or named customers; revenue mechanics are intended to be pharmaceutical product sales through standard pharmaceutical supply chains to healthcare providers and pharmacies following regulatory approval. Pricing is not publicly disclosed, consistent with clinical-stage status.
Capitalization consists of approximately €1.9 million raised in the first close of a €3 million seed round in February 2026, led by Lakeside Capital Ltd (€1.6M equity) with participation from Enterprise Ireland, The Boole Investment Syndicate, and DeepIE Ventures, plus €0.3M in converted convertible loan notes. The team is 1-10 employees led by founder and CEO Dr Waleed Faisal, alongside CFO Darren Cunningham, CDO Erik Doevendans, COO Ryan Bamsey, Director Neil Thomas, and Director Sean Corkery (Lakeside Capital). The company has accumulated multiple Irish innovation awards, including the 2022 Ireland Pharma Industry Awards Innovation of the Year, the 2022 SSPC Commercial Activity of the Year, the 2023 IDEATE Ireland prize, and the 2025 InterTradeIreland All-Island Seedcorn Investor Readiness Competition overall winner designation.
ArrayPatch firmographics
Firmographics- Name
- ArrayPatch
- Legal name
- ArrayPatch Ltd
- Website
- https://array-patch.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ArrayPatch Ltd is a Cork, Ireland-based biotech developing polymer-free dissolving microneedle therapeutics via its DerMap platform, with lead program ITZ-DerMap for nail fungal infections and a pipeline expanding into dermatology, migraine, and peptide therapy indications.
- Ownership category
- akta.pro rank
ArrayPatch industry classification
Industry- Product category
- Dermatological Therapeutics / Drug Delivery Technology
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Nanotechnology (541713)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Needle-Free Injection Systems (Jet Injectors/Microneedle Patches) (HLAHAIAD)
- akta.pro secondary industries
- Dermatology Specialty Pharmaceuticals (HLAIACAL), Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)
Keywords
Where ArrayPatch is headquartered
LocationHeadquarters
- HQ city
- Cork
- HQ country
- Ireland
- HQ region
- Europe
Offices1 record
Markets served
ArrayPatch business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pharmaceutical Product Sales: ArrayPatch is developing pharmaceutical products based on their DerMap microneedle platform. Revenue will be generated through product sales of therapeutic treatments, initially targeting the $6 billion nail fungal infection market.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
ArrayPatch product offering
Product offeringCore offering
ArrayPatch develops polymer-free dissolvable microneedle patch therapeutics through its proprietary DerMap platform, in which each microneedle is made entirely from the drug substance itself, enabling greater drug loading and pain-free intradermal delivery. Its lead clinical asset, ITZ-DerMap, targets onychomycosis (nail fungal infection) via a 505(b)(2) regulatory pathway, with pipeline expansion planned into skin cancer, skin ageing, migraines, and small peptide therapies for diabetic patients.
Product overview
ArrayPatch is a biotech company developing microneedle-based therapeutics through its proprietary DerMap platform. The platform enables pain-free drug delivery via polymer-free dissolving microneedles, with each microneedle made entirely from the drug treatment. The lead product is ITZ-DerMap for treating onychomycosis (nail fungus), with the company pursuing a 505(b)(2) regulatory pathway. The company has also acquired peptide delivery technology from Vitropep to expand into peptide therapeutics for diabetes and cardiovascular disease. The pipeline is expanding into additional indications including skin cancer, skin ageing, migraines, and small peptide therapies.
Differentiator
Problem solved
Functional benefit
Products and services
- DerMap Platform Proprietary polymer-free dissolvable microneedle patch platform that delivers medication pain-free through the skin. Each microneedle is composed entirely of the active drug substance, eliminating polymer carriers and enabling higher drug loading than conventional microneedle designs. The platform is the foundation for ArrayPatch's clinical pipeline across multiple dermatology and systemic indications.
- ITZ-DerMap Lead therapeutic program derived from the DerMap platform, targeting onychomycosis (nail fungal infection). Uses polymer-free dissolving microneedles to deliver itraconazole (ITZ) pain-free through the nail and surrounding skin, with a particular focus on high-risk diabetic patients. Pursuing 505(b)(2) regulatory route in the $6 billion nail fungal infection market.
- Microneedle Patch Peptide Delivery Technology Peptide delivery technology acquired from Vitropep and integrated with the DerMap microneedle platform, enabling intradermal delivery of peptide therapeutics for indications such as diabetes and cardiovascular disease.
Quantifiable outcome
- Targeting $6 billion nail fungal infection market
Companies that use ArrayPatch
Customer profileSegments3 records
Ideal customer profiles2 records
ArrayPatch technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ArrayPatch partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- VitropepsupportingArrayPatch acquired peptide delivery technology from Vitropep to enhance its microneedle-based therapeutic platform. The acquisition expands the company's capacity to develop new peptide therapeutics for health challenges like diabetes and cardiovascular disease.
Scale indicators3 records
Recent moves5 records
Expansion highlights6 records
ArrayPatch competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key highlights6 records
Customer concentration
ArrayPatch social profiles
Digital presenceArrayPatch financial estimates
Financial estimateRevenue estimate
Valuation estimate
ArrayPatch leadership team
Management profileNumber of profiles
Profiles6 records
ArrayPatch funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ArrayPatch M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ArrayPatch
What does ArrayPatch do?
ArrayPatch develops polymer-free dissolvable microneedle patch therapeutics through its proprietary DerMap platform, in which each microneedle is made entirely from the drug substance itself, enabling greater drug loading and pain-free intradermal delivery. Its lead clinical asset, ITZ-DerMap, targets onychomycosis (nail fungal infection) via a 505(b)(2) regulatory pathway, with pipeline expansion planned into skin cancer, skin ageing, migraines, and small peptide therapies for diabetic patients.
Is ArrayPatch a public or private company?
ArrayPatch is a private company. It is classified as venture growth investor backed and is currently operating.
When was ArrayPatch founded?
ArrayPatch was founded in 2024. It employs 1 to 10 people.
Where is ArrayPatch based?
ArrayPatch is headquartered in Cork, Ireland, in the Europe region.
How does ArrayPatch make money?
One revenue line is on record: pharmaceutical Product Sales.
Does ArrayPatch have an API?
No public API is recorded for ArrayPatch.
What industry is ArrayPatch in?
ArrayPatch's product category is Dermatological Therapeutics / Drug Delivery Technology. Its primary akta.pro industry code is HLAHAIAD, Needle-Free Injection Systems (Jet Injectors/Microneedle Patches), with a secondary code of HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 3841.